Your browser doesn't support javascript.
loading
Inflawell® improves neutrophil-to-lymphocyte ratio and shortens hospitalization in patients with moderate COVID-19, in a randomized double-blind placebo-controlled clinical trial.
Barzin Tond, Sepideh; Balenci, Laurent; Khajavirad, Nasim; Salehi, Mohammadreza; Tafakhori, Abbas; Shahmohammadi, Mohammad Reza; Ghiasvand, Fereshteh; Jafari, Sirous; Abolghasemi, Sara; Mokhtari, Farzad; Mahmoodi Baram, Somayyeh; Zarei, Tayebe; Kazemi, Davood; Mohammadnejad, Esmaeil; Shah-Hosseini, Akram; Haghbin Toutounchi, Alireza; Fallah, Soudabeh; Riazi, Ali; Karima, Saeed.
Afiliación
  • Barzin Tond S; Department of Clinical Biochemistry, School of Medicine, Shahid Beheshti University of Medical Sciences (SBMU), Tehran, Iran.
  • Balenci L; Kondor Pharma Inc, Toronto, Canada.
  • Khajavirad N; Internal Medicine Department, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
  • Salehi M; Department of Infectious Diseases, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
  • Tafakhori A; Department of Neurology, School of Medicine, Iranian Center of Neurological Research, Neuroscience Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
  • Shahmohammadi MR; Functional Neurosurgery Research Center, Shohada Tajrish Comprehensive Neurosurgical Center of Excellence, Shahid Beheshti University of Medical Sciences (SBMU), Tehran, Iran.
  • Ghiasvand F; Department of Infectious Diseases, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
  • Jafari S; Department of Infectious Diseases, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
  • Abolghasemi S; Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medial Sciences (SBMU), Tehran, Iran.
  • Mokhtari F; Kondor Pharma Inc, Toronto, Canada.
  • Mahmoodi Baram S; Kondor Pharma Inc, Toronto, Canada.
  • Zarei T; Clinical Trial Department, Behbalin Inc, Tehran, Iran.
  • Kazemi D; Clinical Trial Department, Behbalin Inc, Tehran, Iran.
  • Mohammadnejad E; Department of Infectious Diseases, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
  • Shah-Hosseini A; Department of Medical-Surgical Nursing and Basic Sciences, School of Nursing & Midwifery, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
  • Haghbin Toutounchi A; Department of Clinical Biochemistry, School of Medicine, Shahid Beheshti University of Medical Sciences (SBMU), Tehran, Iran.
  • Fallah S; Department of Clinical Biochemistry, School of Medicine, Shahid Beheshti University of Medical Sciences (SBMU), Tehran, Iran.
  • Riazi A; Department of Biochemistry, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.
  • Karima S; Kondor Pharma Inc, Toronto, Canada.
Inflammopharmacology ; 30(2): 465-475, 2022 Apr.
Article en En | MEDLINE | ID: mdl-35201518
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Tratamiento Farmacológico de COVID-19 / Neutrófilos Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Humans Idioma: En Revista: Inflammopharmacology Asunto de la revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2022 Tipo del documento: Article País de afiliación: Irán
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Tratamiento Farmacológico de COVID-19 / Neutrófilos Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Humans Idioma: En Revista: Inflammopharmacology Asunto de la revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2022 Tipo del documento: Article País de afiliación: Irán